Welcome!

The Cancer Discovery Hub (CDH) is a one-stop pan-omics diagnostic and research core laboratory housed at the National Cancer Centre Singapore. We specialise in state-of-the-art research-grade technologies and provide expert support to investigators on all cancer related projects.

Home: Welcome

Latest news

Jan 8, 2023

Precision Nutrition- Impact of Durian Consumption on Human Microbiome and Metabolome (DURIOME)

Apr 15, 2022

Rare Cancers - Not As Rare As You Think They Are

Feb 24, 2022

Discovery of PAI-1 as a novel target for ligand inhibition in peritoneal carcinomatosis

Key events and achievements

10 April 2023 : Poster Presentations + Scholar-in-Training Award, AACR Annual Meeting, Florida, USA (Jing Yi Lee, Tun Kiat Ko)
02 April 2024 : Collaborative research agreement with Illumina
01 Nov 2023: Poster Presentation, CTOS Annual Meeting, Dublin (Elizabeth Lee)
15 Sep 2023 : MOU and RCA signed with Agilent Technologies, BioSyngen, BGI Research and MGI Tech
14 June 2023 : Poster Presentation, ICML Lugano, Switzerland
14 April 2023 : Poster Presentation, AACR Annual Meeting, Florida, USA (Bavani Kannan)
20 Mar 2023 : ESMO Merit Award, ESMO Sarcoma and Rare Cancers Congress, Lugano, Switzerland
18 Mar 2023 : Co-organizer, Singapore Lymphoma Scientific Symposium 2023
12 Dec 2022 : Oral abstract, ASH Annual Meeting, New Orleans, USA
09 Dec 2022 : Invited presentation, Stem Cell Society Singapore (SCSS) Symposium (Nimmi Baby)
17 Nov 2022 : Oral paper, CTOS Annual Meeting, Vancouver, Canada (Jing Yi Lee)
19 Aug 2022 : Invited speech, 6th International BRCA Forum, Singapore
19 Aug 2022 : Collaborative research agreement with Scinnohub Pharmaceutical
19 Aug 2022 : Collaborative research agreement with MGI Tech
04 Aug 2022 : Collaborative research agreement with Twist Bioscience
16 Jun 2022 : Best Oral Presentation, International Congress of the Asian Oncology Society (AOS 2022), South Korea (Tun Kiat Ko)
12 Apr 2022 : Invited Oral Presentation at Major Symposium, AACR Annual Meeting, New Orleans, US
22 Feb 2022 : Publication on circulating tumor DNA mutations in progressive gastrointestinal stromal tumors, Frontiers in Oncology
17 Feb 2022 : Travel Award for Poster abstract at Japanese Society of Medical Oncology Annual Meeting, Japan (Elizabeth Lee)
12 Jan 2022 : Commercial launch of the UNITED NGS Assay (Lucence) for Asian prevalent cancers at the NCCS
21 Oct 2021 : Collaborative research agreement with STEMCELL Technologies
01 Sep 2021 : Collaborative research agreement with SymBio Pharmaceuticals on EBV-positive lymphomas
01 Sep 2021 : Official launch of Cancer Discovery Hub!

Home: Services

Start a project consultation with us

Discuss with our team on study feasibility, experimental design, manpower requirements, project costs, specific service needs and collaboration opportunities.

Featured Publications

Scientific publications supported by the Cancer Discovery Hub

Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies
Gut. 2023

Nov, 2023

Link to publication

Objectives: Cholangiocarcinoma (CCA) is a heterogeneous malignancy with high mortality and dismal prognosis, and an urgent clinical need for new therapies. Knowledge of the CCA epigenome is largely limited to aberrant DNA methylation. Dysregulation of enhancer activities has been identified to affect carcinogenesis and leveraged for new therapies but is uninvestigated in CCA. Our aim is to identify potential therapeutic targets in different subtypes of CCA through enhancer profiling.

Design: Integrative multiomics enhancer activity profiling of diverse CCA was performed. A panel of diverse CCA cell lines, patient-derived and cell line-derived xenografts were used to study identified enriched pathways and vulnerabilities. NanoString, multiplex immunohistochemistry staining and single-cell spatial transcriptomics were used to explore the immunogenicity of diverse CCA.

Results: We identified three distinct groups, associated with different etiologies and unique pathways. Drug inhibitors of identified pathways reduced tumour growth in in vitro and in vivo models. The first group (ESTRO), with mostly fluke-positive CCAs, displayed activation in estrogen signalling and were sensitive to MTOR inhibitors. Another group (OXPHO), with mostly BAP1 and IDH-mutant CCAs, displayed activated oxidative phosphorylation pathways, and were sensitive to oxidative phosphorylation inhibitors. Immune-related pathways were activated in the final group (IMMUN), made up of an immunogenic CCA subtype and CCA with aristolochic acid (AA) mutational signatures. Intratumour differences in AA mutation load were correlated to intratumour variation of different immune cell populations.

Conclusion: Our study elucidates the mechanisms underlying enhancer dysregulation and deepens understanding of different tumourigenesis processes in distinct CCA subtypes, with potential significant therapeutics and clinical benefits.

Contact us

Home: Contact